Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00035035 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

A Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
20
Study locations

NCT00035035 is a Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm that has completed, run by Eli Lilly and Company. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00035035, a Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
20
Study locations

Study Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Conditions Studied

Pancreatic Neoplasms Metastases, Neoplasm

Interventions

  • DRUG ALIMTA
  • DRUG GEMZAR

Study Locations (20)

California

  • - Fountain Valley
  • - Fullerton
  • - Lancaster
  • - Los Angeles
  • - Pomona
  • - Santa Rosa
  • - Torrance

Illinois

  • - Chicago
  • - Decatur
  • - Harvey

Florida

  • - Lake Worth
  • - Miami

Kentucky

  • - Crestview Hills
  • - Louisville

Alabama

  • - Huntsville

Colorado

  • - Fort Collins

Connecticut

  • - Hartford

Indiana

  • - Indianapolis

Trial Details

FieldValue
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00035035

The ClinicalTrials.gov registry entry for NCT00035035 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which ALIMTA is the first listed.

NCT00035035 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT00035035 about?

NCT00035035 is a clinical study titled "A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.". Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their ...

What is the current status of trial NCT00035035?

This trial is currently completed. It is a Phase 3 study.

What conditions does trial NCT00035035 study?

This clinical trial studies the following conditions: Pancreatic Neoplasms, Metastases, Neoplasm.

What interventions are being tested in trial NCT00035035?

The interventions under investigation include: ALIMTA (DRUG), GEMZAR (DRUG).

Who is sponsoring clinical trial NCT00035035?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00035035 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Neoplasms

All registered trials for this condition

Metastases, Neoplasm

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.